Biotech Business Developments: June 04 - 11

📊 Analyzed 74 biotech business articles from 9 sources

Subscribe to Genomely for the latest discoveries and in-depth analyses in your inbox

Thank you for subscribing and for your continued support and passion for science!

---

About This Curation

These top 10 stories were automatically selected from 70 biotech business articles analyzed this week using our scoring algorithm. Each story is scored based on deal size, event significance, company prominence, innovation factor, and source credibility.

⭐ 10 Mos Exciting Stories This Week

#1 GSK boosts cancer pipeline with $11B Nuvalent buyout

BioPharma Dive

June 09, 2026

[Read Full Story] GSK acquired Nuvalent for $11 billion, gaining two late-stage lung cancer drugs currently under FDA review for treating ALK-positive and ROS1-positive non-small cell lung cancer. The deal marks GSK’s third acquisition this year and aims to establish a major franchise in precision oncology, a category projected to reach $70 billion by 2030.

#2 GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in lung cancer

FierceBiotech

[Read Full Story] GSK will acquire Nuvalent for $10.6 billion, gaining two late-stage lung cancer drugs expected to reach approval soon. The deal positions GSK to compete directly with Roche’s Rozlytrek and Pfizer’s Lorbrena in the targeted lung cancer market, giving the pharma giant an immediate foothold in a growing oncology segment where it currently lacks presence.

#3 Novartis and Orionis strike second molecular glue deal for $40M upfront

Endpoints News

June 10, 2026

[Read Full Story] Novartis signed a second molecular glue partnership with Orionis Biosciences, paying $40 million upfront with potential milestone payments reaching $1.4 billion. The deal reinforces Novartis’s commitment to the emerging molecular glue degrader field, where the Swiss pharma giant is building a portfolio through multiple partnerships with specialized biotechs. Molecular glue degraders represent a hot therapeutic modality that selectively destroys disease-causing proteins, attracting significant investment from major pharmaceutical companies.

#4 Galmed acquires Colospan in $4.5M deal as it eyes $6B GI dx market

FierceBiotech

[Read Full Story] Galmed Pharmaceuticals bought Colospan for $4.5 million to enter the gastrointestinal diagnostics market, which is valued at $6 billion. The acquisition gives the Israel-based biotech a platform to compete in a large diagnostic sector beyond its existing therapeutic focus. Galmed is betting it can capture meaningful share of a market worth over 1,300 times its acquisition cost.

#5 Incyte’s $1.25B Buyout Brings What Could Become the Next Big Bleeding Disorder Drug

MedCity News

June 08, 2026

[Read Full Story] Incyte acquired Vega Therapeutics for $1.25 billion to gain a late-stage drug for von Willebrand disease that offers a new mechanism of action and dosing advantages over existing treatments. The acquisition addresses Incyte’s need for revenue diversification as its top-selling drug Jakafi faces approaching patent expiration. The deal gives Incyte access to a potential blockbuster in a bleeding disorder market currently served by older therapies.

#6 Parabilis sets a record with a $670M biotech IPO

BioPharma Dive

June 10, 2026

[Read Full Story] Parabilis raised $670 million in the largest IPO ever for a venture-backed biotech company, marking the 12th major public offering in 2026. The deal extends a strong year for biotech fundraising, with drug startups collectively securing over $4.1 billion through IPOs. The record-breaking raise signals sustained investor appetite for biotech assets and provides Parabilis substantial capital to advance its drug development programs.

#7 Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

BioPharma Dive

June 11, 2026

[Read Full Story] Takeda’s experimental TYK2 inhibitor zasocitinib outperformed Bristol Myers Squibb’s approved Sotyktu in a direct comparison trial, a rare head-to-head study that could reshape the competitive landscape for this drug class. The results validate Takeda’s $4 billion investment in the program and position zasocitinib as a potential best-in-class treatment. A win in this closely watched matchup gives Takeda concrete differentiation data that typically drives prescriber decisions and payer coverage—critical advantages in crowded immunology markets.

#8 Cohere open-sources a coding agent that runs on a single H100

VentureBeat

June 09, 2026

[Read Full Story] This article is about AI coding tools, not biotech. Cohere released North Mini Code, a 30 billion parameter open-source coding model that runs on a single H100 GPU, offering engineering teams an alternative to managed models like Claude. The model generates three times more output tokens than comparable models, creating cost concerns for high-volume production use despite eliminating API dependency.

#9 Lilly offers up to $1B for Alzheimer’s drug; Bial cuts failed Parkinson’s drug

Endpoints News

June 09, 2026

[Read Full Story] Eli Lilly signed a deal worth up to $1 billion for an Alzheimer’s drug candidate, paying $10 million upfront with the remainder tied to development and commercial milestones. Separately, Bial discontinued development of a failed Parkinson’s disease drug. The moves reflect continued heavy investment in Alzheimer’s treatments despite recent setbacks across the neuroscience sector, while companies cut losses on unsuccessful programs.

#10 Cancer-focused Parabilis’ upsized $670M IPO breaks new record for biotechs

FierceBiotech

[Read Full Story] Parabilis Medicines raised $670 million in its IPO, setting a new record for the largest biotech listing ever. The cancer-focused company’s upsized offering exceeded initial expectations, signaling strong investor appetite for oncology assets despite broader market uncertainty.